Alpha Teknova 2025 Q3 Earnings Revenue Grows 9%, Net Loss Narrows 43%

Alpha Teknova (TKNO) reported Q3 2025 earnings on Nov 8, 2025, . The results beat revenue expectations and narrowed losses, .

Revenue

, , which offset a 13% decline in Clinical Solutions to $1.7 million. The Lab Essentials segment, comprising catalog and custom products, benefited from higher average revenue per customer and operational efficiencies. Meanwhile, Clinical Solutions faced challenges, with lower average revenue per customer despite an expanded customer base.

Earnings/Net Income

, , in Q3 2025, , , loss in Q3 2024. , reflecting reduced non-recurring inventory charges and operational gains. While the EPS remains negative, the sequential improvement highlights progress in cost management and margin recovery.

Post-Earnings Price Action Review

Following the earnings report, Alpha Teknova’s stock experienced mixed short-term performance. . The post-earnings reaction underscores investor caution amid ongoing losses and uncertainty about the biotech funding environment.

CEO Commentary

, President and CEO: “We feel like we are in a really good spot to let the rest of our strategy play out.” Emphasizing operational efficiency and customer diversification, Gunstream highlighted the Lab Essentials segment’s resilience and the potential for long-term growth as Clinical Solutions customers advance therapies toward commercialization. The tone was cautiously optimistic, acknowledging challenges in the biopharma sector while reaffirming confidence in the company’s strategic direction.

Guidance

. , which is less sensitive to biotech funding cycles. .

Additional News

1. Collaboration, targeting markets. The synthetic, .

2. Q3 Earnings Call: The company hosted a webcast and conference call on Nov 6, 2025, to discuss Q3 results, with management addressing biotech funding trends and operational progress.

3. Q2 Financial Results: In August 2025, , , .